Expanding the inclusion criteria for the SATURN trial
You give me too much credit, I missed this. A preclinical study of 011 + MDV3100 is a lot more interesting than one of 011 + cabazitaxel (which may or may not have been done, who knows). If the results presented at ASCO are positive, then if MDV3100 is approved we can hope that Teva will spring for clinical trials of the 011/MDV3100 combo. I recall Cormack saying in a couple of CCs that there's preclinical data showing 011 enhances hormone ablation treatments. I assume they'd have to start with a P1 trial though.
I wonder if they're doing similar preclinical studies combining 011 with abiraterone. Or combining 427, which Cormack has emphasized in recent calls should work hand-in-glove with antiandrogen drugs, with either MDV3100 or abiraterone.